Arkansas HB 1332: TO REQUIRE THE ARKANSAS MEDICAID PROGRAM TO EVALUATE CLAIMS FOR DIAGNOSES FREQUENCY OF OBESITY-RELATED CONDITIONS AND PRESENT THE COSTS.

Bill Text

*.JMB658* JMB658 - 04-08-2025 09:25:16 Page 1 of 3

Hall of the House of Representatives
95th General Assembly - Regular Session, 2025
Amendment Form

______________________________________________________________________
Subtitle of House Bill 1332
TO REQUIRE THE ARKANSAS MEDICAID PROGRAM TO COVER GLUCAGON-LIKE
PEPTIDE-1 RECEPTOR AGONISTS, ALSO KNOWN AS GLP-1 AGONISTS, WHEN
PRESCRIBED FOR WEIGHT LOSS.
______________________________________________________________________

Amendment No. 2 to House Bill 1332

Amend House Bill 1332 as engrossed H3/31/25 (version: 3/31/25 11:41:50 AM):

Add Senator J. Scott

AND

Page 1, delete lines 10 through 12, and substitute the following:
"EVALUATE CLAIMS FOR DIAGNOSES FREQUENCY OF OBESITY-RELATED CONDITIONS AND
PRESENT THE COSTS; TO ALLOW HEALTH BENEFIT PLANS TO OFFER OPTIONAL COVERAGE
OF UNITED STATES FOOD AND DRUG ADMINISTRATION-APPROVED ANTI-OBESITY
MEDICATION; AND FOR OTHER PURPOSES."

AND

Delete the subtitle in its entirety and substitute:

"TO REQUIRE THE ARKANSAS MEDICAID PROGRAM
TO EVALUATE CLAIMS FOR DIAGNOSES
FREQUENCY OF OBESITY-RELATED CONDITIONS
AND PRESENT THE COSTS."

AND

JMB658 - 04-08-2025 09:25:16 Amendment No. 2 to House Bill 1332 Page 2 of 3

Delete everything after the enacting clause and substitute the following:
"SECTION 1. Arkansas Code Title 20, Chapter 77, Subchapter 154, is
amended to add an additional section to read as follows:
20-77-154. Obesity-related conditions.
(a) The Department of Human Services shall evaluate claims level data
for diagnoses frequency of obesity-related conditions including without
limitation Type 2 diabetes, pre-diabetes, cardiovascular disease, heart
failure, hypertension, chronic kidney disease, metabolic dysfunction-
associates steatohepatitis, liver disease, obstructive sleep apnea,
osteoarthritis, and other obesity-related conditions within the Medicaid
population.
(b) The department shall document the cost of these obesity-related
conditions and show trend data, year over year of the rising trends of both
the diagnoses frequency and cost to the state to present at least sixty (60)
days before a regular or fiscal legislative session to the:
(1) House Committee on Public Health, Welfare, and Labor; and
(2) Senate Committee on Public Health, Welfare, and Labor.

SECTION 2. Arkansas Code Title 23, Chapter 79, Subchapter 1, is
amended to add an additional section to read as follows:
23-79-169. Optional coverage for United States Food and Drug
Administration-approved anti-obesity medications — Definition.
(a) As used in this section, "United States Food and Drug
Administration-approved anti-obesity medication" means a medication approved
by the United States Food and Drug Administration with an indication for
weight management in patients with chronic obesity.
(b)(1) A health benefit plan that is offered, issued, or renewed in
this state shall allow the policyholder the option to purchase coverage for
United States Food and Drug Administration-approved anti-obesity medications.
(2) The health benefit plan may adopt standards and criteria
that a covered person shall meet to be eligible for United States Food and
Drug Administration-approved anti-obesity medications consistent with
standards established by rule of the State Insurance Department.
(c) Subsection (b) of this section does not apply to a government

JMB658 - 04-08-2025 09:25:16 Amendment No. 2 to House Bill 1332 Page 3 of 3

self-insured plan."

The Amendment was read ________________________________________________________________________________
By: Representative Pilkington
JMB/JMB - 04-08-2025 09:25:16 _________________________
JMB658 Chief Clerk